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Objective: We aimed to investigate the changes in blood glucose levels, body weight, and 
metabolic and circulatory parameters during daily administration of the sodium-glucose 
cotransporter 2 inhibitor, dapagliflozin, as well as to examine its safety and the factors that predict 
its effects on blood glucose and body weight in a retrospective, multicenter study conducted at 6 
medical institutions in the Chikushi region of Kyushu, Japan.  
Methods: A total of 112 people with type 2 diabetes treated with dapagliflozin participated in the 
study. Data from blood tests, physical measurements, and other parameters obtained during 
outpatient visits at the start and after 12 months were retrospectively analyzed to evaluate the 
efficacy and safety.  
Results: The mean age of patients was 56.7 ± 9.9 years (mean ± standard deviation). The glycated 
hemoglobin (HbA1c) and body mass index (BMI) at baseline were 8.1 ± 1.2 % and 29.2 ± 4.6 
kg/m2, respectively. Significant reduction was observed in HbA1c (0.66%) and body weight (2.9 
kg) (p <0.01) with dapagliflozin administration.  
After 12 months, blood pressure, liver function parameters (aspartate aminotransferase [AST], 
alanine aminotransferase [ALT], γ-glutamyl transpeptidase [γ-GTP]), uric acid , lipid profile (p 
<0.05) were significantly improved.  
Multiple regression analyses showed that high baseline HbA1c affected the improvement of 
HbA1c. Additionally, female sex and long disease duration affected BMI improvement. 
Regarding the safety, none of the 112 subjects exhibited severe adverse effects related to 
dapagliflozin, and no clinically meaningful changes were observed in the data from blood tests 
and physical measurements obtained during outpatient visits.   
Conclusion: This multicenter study conducted at medical institutions in the Chikushi region of 
Kyushu confirmed the efficacy and safety of dapagliflozin in clinical practice. We identified 
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baseline HbA1c level as a factor that affected the change in HbA1c, and sex and disease duration 




Educating and supporting patients with diabetes is extremely important for preventing both acute 
and chronic diabetic complications [1]. Appropriate blood glucose control in patients with 
diabetes can be achieved through diet and exercise therapy, and if necessary, with 
antihyperglycemic agents. All medical professionals involved in diabetes care are responsible for 
preventing the onset and exacerbation of complications. Sodium-glucose cotransporter 2 
(SGLT2) inhibitors suppress the reabsorption of glucose by selectively inhibiting SGLT2 activity 
on the proximal renal tubules. This results in excretion of excess glucose in the urine, thereby 
lowering blood glucose levels [2]. Several meta-analyses and systematic reviews have verified 
the glucose-lowering effects of SGLT2 inhibitors [3-6], and administration of an SGLT2 inhibitor 
alone was found to have the low risk of hypoglycemia [2]. Besides, SGLT2 inhibitors have been 
shown to reduce body weight, lower blood pressure, improve the lipid profile, lower uric acid 
levels, and have other positive effects on metabolism and circulatory dynamics. Therefore, these 
drugs are expected to lower the risk of cardiovascular events among patients with type 2 diabetes 
[7, 8].  
To address the concerns about using SGLT2 inhibitors in elderly people, postmarketing 
surveillance of SGLT2 inhibitor use in elderly patients with type 2 diabetes was conducted and 
showed safety levels similar to those determined in clinical trials and did not reveal any new 
safety problems [9-13]. Therefore, SGLT2 inhibitors are considered a useful therapeutic option 
for patients with type 2 diabetes, including elderly patients. Therefore, the use of SGLT2 
inhibitors in clinical practice is expected to expand. 
Thus, it is extremely important to verify the safety and efficacy of the daily administration of 
SGLT2 inhibitors to treat patients with type 2 diabetes with various background characteristics. 
Furthermore, given the various actions of SGLT2 inhibitors, including improvement of 
metabolism and circulatory dynamics, a detailed investigation of the changes in blood glucose, 
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body weight, and metabolic and circulatory parameters during SGLT2 inhibitor administration 
could help investigate other clinical applications of these drugs. Therefore, we conducted a 
retrospective, multicenter study at 6 medical institutions in the Chikushi region of Kyushu to 
investigate the changes in blood glucose levels, body weight, metabolic and circulatory 





This study was a multicenter study including 6 medical institutions (Fukuoka University Chikushi 
Hospital, Ito Medical Clinic, Kodera Medical Clinic, Saiseikai Futsukaichi Hospital, Hara 
Hospital, Fukuoka Tokushukai Medical Center) in the Chikushi region of Kyushu, Japan. The 




Patients with type 2 diabetes who received dapagliflozin in outpatient care at the aforementioned 
6 medical institutions from May 2014 to September 2016 were included. All subjects provided 
written informed consents. Patient received blood tests at indicated visits in each medical 
institution before or after meals.  
 
Treatment method 
Oral administration of dapagliflozin was initiated at 5 mg once per day. If the effect was 
insufficient, the dose was increased to 10 mg once per day while observing the patient’s course. 
We analyzed the data of patients who were administered the same doses of anti-diabetic drugs 
during the study period. 
 
Parameters assessed 
To retrospectively analyze clinical data from the start of dapagliflozin administration to 12 
months, the following parameters were assessed. Changes in glycated hemoglobin (HbA1c), 
body weight, casual blood glucose, CPR index (fasting C-peptide (ng/mL) / fasting blood glucose 
(mg/dL) × 100), body mass index (BMI), systolic blood pressure, diastolic blood pressure, pulse 
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rate, aspartate aminotransferase (AST), alanine aminotransaminase (ALT), γ-glutamyl 
transpeptidase (γ-GTP), uric acid, serum creatinine (Cr), estimated glomerular filtration rate 
(eGFR), urinary albumin (mg/gCr), total cholesterol (total-C), low-density lipoprotein cholesterol 
(LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides were examined from 
the start of administration to 12 months. Correlations among change of each parameter from the 
start of administration to 12 months were investigated. Baseline age, sex, disease duration, 
HbA1c, BMI, systolic blood pressure, ALT, eGFR, and HDL-C were analyzed to identify the 
factors that affected the changes in HbA1c and BMI. The incidence of adverse effects was 
assessed in all patients who received dapagliflozin as an indicator of safety. The definition of 
diseases are as follows. DKD (diabetic kidney disease) was defined as a urine 
albumin-to-creatinine ratio ≥ 30mg/gCr. Dyslipidemia was defined as having total-C ≥ 220mg/dl, 
LDL-C ≥ 140mg/dl, triglyceride ≥ 150mg/dl, or HDL-C ≤ 40mg/dl. Hypertension was defined as 
having systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg. Obesity + 
preobesity was defined as BMI ≥ 22kg/m2. Fatty liver was diagnosed with abdominal 
ultrasonography. Hyperuricemia was defined as uric acid ≥ 7.0mg/dl. All individuals with 
dyslipidemia, hypertension, and hyperuricemia received drug treatment.   
 
Analytical methods 
HbA1c and body weight were determined at the start of administration and after 1, 3, 6, and 12 
months. Data at the start of administration were compared to those after 1, 3, 6, and 12 months 
using analysis of variance (ANOVA; multiplicity adjusted with the Holm method). Other clinical 
values, BMI, blood pressure, and pulse rate were measured at the start of administration and after 
12 months, and data were compared using the paired t-test. Correlations were examined using 
Spearman’s rank correlation coefficient. Patient characteristics that affected the changes in 
HbA1c and BMI were identified using multiple regression analysis (stepwise method) with 
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baseline age, sex, disease duration, HbA1c, BMI, systolic blood pressure, ALT, eGFR, and 
HDL-C as the explanatory variables. Data were expressed as the mean ± standard deviation or 
number of patients (ratio). Missing values were supplemented using the last observation carried 
forward method. Statistical analyses were performed using Excel Statistics 2015 ver 2.21 




This study was carried out in accordance with both ethical guidelines based on the Declaration of 
Helsinki and from Ministry of Health, Labour and Welfare of Japan. Prior to starting the study, 
approval was obtained from the Fukuoka University Chikushi Hospital ethical review board. To 
use the data for this study, each institution was notified that the trial would be conducted on an 
opt-out basis, and patients who continued to visit the institutions received an explanation of the 
study from their primary physician to obtain consents. Patients’ privacy was fully considered such 





A total of 112 subjects (63 men and 49 women) with a mean age of 56.7 ± 9.9 years, diabetes 
duration of 10 ± 6 years, HbA1c of 8.1 ± 1.2 %, and BMI of 29.2 ± 4.6 kg/m2 (Table 1) were 
included. At the start of dapagliflozin administration, the majority of patients were using a 
biguanide (66.1 %) or dipeptidyl peptidase-4 inhibitors (54.5 %), with 24.1 % of the patients 
using insulin (Table 2). The main complications were dyslipidemia (67.9 %), hypertension 
(60.7 %), obesity+preobesity (46.4 %), and fatty liver (24.1 %) (Table 3).  
 
HbA1c change 
HbA1c significantly changed from 8.1 ± 1.2% at the start of dapagliflozin administration to 7.8 ± 
1, 7.6 ± 1, 7.5 ± 1 and 7.5 ± 1 % after 1, 3, 6, and 12 months, respectively (p < 0.01; Figure 1). The 
type of anti-diabetic drugs prescribed before dapagliflozin was not related with the changes of 
HbA1c and weight after adding dapagliflozin (Supplement 1). 
 
Body weight change 
Body weight significantly decreased from 77.3 ± 12.8 kg at the start of dapagliflozin 
administration to 76.0 ± 12.7, 75.0 ± 12.7, 74.6 ± 12.9, and 74.3 ± 12.9 kg after 1, 3, 6, and 12 
months, respectively (p < 0.01; Figure 2).  
 
Changes in blood pressure, pulse rate, and clinical examination 
After 12 months of dapagliflozin administration, blood glucose, BMI, systolic blood pressure, 
and diastolic blood pressure significantly decreased, compared to those at the start of 
dapagliflozin administration (p < 0.05) without the changes of pulse rate. HDL-C significantly 
increased (p = 0.002). Significant improvements were observed for all the liver function 
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parameters (AST, ALT, and γ-GTP; p < 0.01). Of the kidney function parameters, only serum Cr 
significantly increased (p < 0.05; Table 4).  
 
Correlations among the parameters assessed 
Correlations among the changes in various parameters after 12 months of dapagliflozin 
administration were analyzed using Spearman’s rank correlation coefficient (Table 5). The 
change in HbA1c showed a significant positive correlation with changes in ALT, γ-GTP, and 
triglycerides (p < 0.05) and a significant negative correlation with the change in HDL-C (p < 
0.001). The change in body weight showed a significant positive correlation with the change in 
ALT and γ-GTP (p < 0.05). The change in ALT and γ-GTP showed a significant positive 
correlation with LDL-C (p < 0.05). 
 
Patient baseline characteristics that affected the change in HbA1c and body weight 
Multiple regression analysis (stepwise method) was used to investigate the patient characteristics 
that affected the changes in HbA1c. Baseline HbA1c was considered a factor that affected the 
changes in HbA1c. Patients with higher HbA1c showed greater improvement in HbA1c than 
those with lower HbA1c. Furthermore, sex and disease duration at baseline were identified as 
factors that affected the changes in BMI. Women and patients with longer disease duration 




No severe adverse effects related to dapagliflozin administration were observed among the 112 
subjects, and there were no clinically meaningful changes in the data from blood tests and 




Clinical trials of new drugs involve a limited number of patients and short duration of 
administration. Therefore, data on administration of new drugs to broader patient populations 
need to be collected in clinical practice. This is particularly important for SGLT2 inhibitors, 
which have novel mechanisms of action and are expected to exhibit various effects, including 
protective actions in the cardiovascular system and other organs. The CVD-REAL2 study 
provided the major real-world evidence on SGLT2 inhibitors [14]. This study compared the 
cardiovascular risk in patients receiving SGLT2 inhibitors and other antidiabetic drugs, as a part 
of their daily medical care. This study included more than 400,000 patients with type 2 diabetes 
from 6 countries, including Japan. Dapagliflozin and other SGLT2 inhibitors reduced the overall 
mortality risk by 49 % (hazard ratio (HR), 0.51; 95 % confidence interval (CI), 0.37-0.7), risk of 
hospitalization owing to heart failure by 36 % (HR, 0.64; 95 % CI, 0.5-0.82), risk of myocardial 
infarction by 19 % (HR, 0.81; 95 % CI, 0.74-0.88), and risk of stroke by 32 % (HR, 0.68; 
95,%,CI, 0.55-0.84). We as clinicians have been interested in the benefits of SGLT2 inhibitors to 
the cardiovascular system. 
In the present multicenter study including 6 medical institutions in the Chikushi region of Kyushu, 
Japan, we retrospectively examined the effects of dapagliflozin on blood glucose, body weight, 
blood pressure, uric acid, lipid profiles, liver and kidney function parameters, urinary protein, and 
other parameters in patients with type 2 diabetes in clinical practice. In addition, we investigated 
the patient characteristics that affected the changes in HbA1c and BMI.  
The main complications of the subjects included in this study were dyslipidemia, hypertension, 
obesity, and fatty liver, indicating that metabolic syndrome affected many of the subjects. The 
average age was 56.7 years, showing that young age groups were also included. Patients were 
obese, had relatively high HbA1c levels, and had been diabetic for a long time. Administration of 
dapagliflozin improved their blood pressure, liver function parameters (AST, ALT, and γ-GTP), 
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uric acid, and lipid profiles, which suggested that dapagliflozin might have positive effects on the 
metabolism and circulatory dynamics. Among these, changes in the liver function parameters, 
ALT and γ-GTP positively correlated with the changes in HbA1c and body weight. This indicated 
that patients in whom dapagliflozin improved HbA1c levels and reduced body weight might also 
exhibit improved liver functions. Hyperglycemia may increase the transcriptional activity of 
genes related to lipid synthesis in the liver resulting in fatty liver [15], and ectopic fats 
accumulated in the liver can induce insulin resistance [16]. In the present study, we showed that 
dapagliflozin administration improved hyperglycemia and obesity in patients with type 2 diabetes 
with complicating metabolic syndrome, which, in turn, suppressed the accumulation of fat in the 
liver, thereby improving liver functions. Furthermore, other studies found that ALT levels 
decreased after administration of dapagliflozin or other SGLT2 inhibitors to patients with type 2 
diabetes patients [17-20]. In rodents, SGLT2 inhibitors have been found to suppress fatty liver 
and lower ALT levels [21, 22]. In addition, hepatocytes obtained from liver biopsies of patients 
with type 2 diabetes receiving SGLT2 inhibitors showed reduced fatty changes [23]. Moreover, 
SGLT2 inhibitors are expected to improve non-alcoholic fatty liver disease (NAFLD), which 
often complicates type 2 diabetes [24, 25]. Interestingly, Changes in ALT, γ-GTP also positively 
correlated with the change in LDL-C. This correlation may be due to improved glycemic control 
and/or insulin resistance as a confounding factor. 
Our investigation of the patient characteristics that affected the change in HbA1c showed that 
patients with high HbA1c levels exhibited larger improvements in HbA1c. A phase III trial of 
dapagliflozin in Asian subjects showed that the mean HbA1c declined from 8.26 % at baseline to 
7.22 and 7.15 % after 6-month dapagliflozin administration at 5 and 10 mg, respectively [26]. 
Moreover, dapagliflozin administration to Japanese subjects lowered HbA1c from 7.5% at 
baseline to 7.09 and 7.05 % at doses of 5 and 10 mg, respectively [27]. The magnitude of HbA1c 
change observed in the present study was in between those reported in these previous studies, 
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possibly owing to the different baseline HbA1c values. Furthermore, female sex and long disease 
duration were associated with large improvements in BMI. These factors are of great interest and 
merit further investigation in larger populations with analysis of a greater number of background 
factors to identify patients with type 2 diabetes who are expected to benefit more from 
dapagliflozin treatment. In terms of safety, dapagliflozin administration did not cause any major 
side effects, and no clinically meaningful changes were observed in the vital signs or kidney and 
liver function parameters. Although an increase in urinary tract and genital infections was 
reported after 4-year dapagliflozin administration, the incidence decreased over time [28]. This 
indicated that dapagliflozin is relatively safe for clinical use as long as it is administered carefully 
with full consideration of safety.  
According to the IDF Diabetes Atlas 8th Edition 2017 [29], there were 425 million patients with 
diabetes worldwide in 2017, and the number is predicted to increase to 629 million by 2045. The 
number of patients with diabetes is expected to increase in developed countries with the increase 
in age and obesity. For appropriate treatment diabetes, more effective therapeutic approaches 
should be established. This multicenter study was planned and conducted in search of more 
effective therapeutic approaches for diabetes. 
 
Conclusion 
This multicenter study conducted at 6 medical institutions in the Chikushi region of Kyushu 
confirmed the safety and positive effects of dapagliflozin on blood glucose in clinical practice. 
Improvements in blood pressure, liver function parameters (AST, ALT, and γ-GTP), uric acid, 
and lipid profiles were also observed. Moreover, baseline HbA1c was shown to positively 
correlate with HbA1c improvement, and female sex and longer disease duration were related to 
BMI improvement. This indicated that dapagliflozin might have positive effects on the 
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Table 1 Baseline characteristics 
Characteristic n Value 
Age (years) 112 56.7 ± 9.9 
Sex (male / female, n [%]) 112 63 [56.3]/49 [43.8] 
Duration of diabetes (years) 108 10.0 ± 6.0 
HbA1c (%) 112 8.1 ± 1.2 
Casual plasma glucose (mg/dL) 110 187.0 ± 64.4 
CPR index 25 2.1 ± 1.1 
Body weight (kg) 104 77.3 ± 12.8 
BMI (kg/m2) 102 29.2 ± 4.6 
Systolic blood pressure (mmHg) 105 133.1 ± 14.2 
Diastolic blood pressure (mmHg) 105 79.7 ± 9.5 
AST (U/L) 109 30.4 ± 19.6 
ALT (U/L) 109 35.7 ± 23.2 
γ-GTP (IU/L) 111 52.8 ± 84.4 
Uric acid (mg/dL) 104 5.6 ± 1.4 
Creatinine (mg/dL) 112 0.7 ± 0.2 
eGFR (mL/min/1.73m2) 112 83.1 ± 21.8 
Urine albumin excretion (mg/gCre) 80 49.2 ± 61.4 
Total-C (mg/dL) 66 198.5 ± 33.9 
LDL-C (mg/dL) 74 117.2 ± 25.4 
HDL-C（mg/dL） 110 52.1 ± 11.2 
Triglyceride（mg/dL） 110 183.9 ± 104.9 





Table 2 Glucose-lowering drugs used at baseline   
Glucose-lowering drugs N = 112 
Biguanide 74 (66.1) 
DPP-4 inhibitors 61 (54.5) 
Sulfonylurea 39 (34.8) 
Thiazolidinediones 11 (9.8) 
α-glucosidase inhibitors 8 (7.1) 
Meglitinides 2 (1.8) 
DPP-4 inhibitor + biguanide 1 (0.9) 
DPP-4 inhibitor +Thiazolidinediones 1 (0.9) 
GLP-1 receptor agonists 6 (5.4) 
Insulin 27 (24.1) 
Data are expressed as numbers (%). DPP-4: dipeptidyl peptidase-4, 




Table 3 Comorbidities at baseline  




Dyslipidemia 76 (67.9) 
Hypertension 68 (60.7) 
Obesity+preobesity 52 (46.4) 
Fatty liver 27 (24.1) 
Hyperuricemia 9 (8.0) 
Insomnia 6 (5.4) 
Brain stroke 4 (3.6) 
Myocardial infarction 3 (2.7) 
Angina 2 (1.8) 




Table 4 Changes in clinical parameters 
 n Baseline 12 months p 
Casual plasma glucose (mg/dl) 110 187.0 ± 64.4 158.7 ± 51.0 < 0.001** 
CPR index 7 1.9 ± 0.5 3.6 ± 2.9 0.183 
BMI (kg/m2) 84 29.5 ± 4.7 28.3 ± 4.7 < 0.001** 
Systolic blood pressure (mmHg) 104 132.8 ± 13.8 128.6 ± 14.4 0.009** 
Diastolic blood pressure (mmHg) 104 79.5 ± 9.1 76.8 ± 10.2 0.019* 
Pulse (beats/min) 87 81.0 ± 11.5 80.4 ± 12.1 0.678 
AST (U/L) 108 30.6 ± 19.6 26.6 ± 14.8 0.008** 
ALT (U/L) 108 35.9 ± 23.2 30.9 ± 22.7 0.006** 
γ-GTP (IU/L) 110 53.2 ± 84.7 41.6 ± 48.2 0.005** 
Uric acid (mg/dL) 102 5.6 ± 1.4 5.2 ± 1.5 < 0.001** 
Creatinine (mg/dL) 111 0.72 ± 0.22 0.76 ± 0.26 0.025* 
eGFR (mL/min/1.73m2) 111 83.1 ± 21.9 80.7 ± 24.1 0.065 
Urinary albumin excretion (mg/gCre) 63 46.4 ± 57.2 50.1 ± 96.5 0.730 
Total-C (mg/dL) 65 198.2 ± 34.1 193.6 ± 30.5 0.113 
LDL-C (mg/dL) 72 117.2 ± 25.7 112.8 ± 24.8 0.160 
HDL-C (mg/dL) 109 51.9 ± 11.0 54.0 ± 11.5 0.002** 
Casual triglyceride (mg/dL) 109 183.8±105.4 203.1 ± 256.3 0.294 
Data are expressed as the means ± standard deviation and missing values were complemented by 
the last observation carried forward method. 
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*p < 0.05, **p < 0.01 (vs. baseline, paired t-test) 
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Table 5 Correlations among the changes in various parameters after 12 months of dapagliflozin administration 
 ΔHbA1c ΔBW ΔcPG ΔCPRi ΔBMI ΔSBP ΔDBP Δpulse ΔAST ΔALT Δγ-GTP ΔUA ΔCre ΔeGFR Δu-Alb ΔTotal-C ΔLDL-C ΔHDL-C ΔTG 
ΔHbA1c 1.0000 0.1789 0.4968* 0.7857* 0.1446 0.0773 0.0292 0.1112 0.1641 0.2436* 0.3029* 0.0814 -0.0695 0.0664 0.1008 -0.1028 -0.0222 -0.4517* 0.3150* 
ΔBW  1.0000 0.1693 0.3063 0.9434* 0.1364 0.0096 -0.0753 0.1915 0.2506* 0.2785* 0.1956 0.1267 -0.1284 0.2106 0.0814 -0.0207 -0.1295 0.0941 
ΔcPG *  1.0000 0.5000 0.2175* 0.1312 0.0119 0.2195* 0.0990 0.1267 0.2108* 0.0711 0.1214 -0.1208 -0.0093 -0.2404 0.0215 -0.2550 0.2486 
ΔCPRi *   1.0000 -0.1071 -0.3424 -0.3214 -0.4643 0.0371 0.2143 -0.3120 0.8649* 0.0714 -0.2143 0.1482 0.3571 0.1429 -0.3063 0.7388 
ΔBMI  * *  1.0000 0.1307 -0.0641 -0.0385 0.1008 0.1607 0.1985 0.0941 0.0923 -0.0814 0.2253 0.0766 -0.0444 -0.1342 0.1132 
ΔSBP      1.0000 0.5154* 0.0512 0.0312 0.0246 0.1851 -0.0521 -0.2304* 0.2286* 0.0567 -0.3844* 0.0111 -0.2212* 0.0765 
ΔDBP      * 1.0000 -0.0104 -0.0095 0.0320 0.0426 -0.0818 -0.2287* 0.2130* -0.0096 -0.3014* 0.0649 -0.1873 0.1010 
Δpulse   *     1.0000 0.0494 0.0153 0.0643 -0.0397 0.2136* -0.1230 0.0204 0.0348 0.0186 -0.0334 0.1658 
ΔAST         1.0000 0.8704* 0.6864* 0.0424 0.0454 0.0122 0.1834 0.0593 0.2504* -0.0845 -0.0088 
ΔALT * *       * 1.0000 0.7339* 0.0903 0.0066 0.0531 0.1811 0.0487 0.2694* -0.1674 0.0538 
Δγ-GTP * * *      * * 1.0000 0.0730 0.0740 -0.0075 0.1826 -0.0800 0.3496* -0.2075* 0.1811 
ΔUA    *        1.0000 0.3236* -0.3068* -0.0705 0.1227 0.0378 -0.0901 0.1655 
ΔCr      * * *    * 1.0000 -0.9236* -0.1514 0.1009 0.0854 0.0793 0.0243 
ΔeGFR      * *     * * 1.0000 0.1585 -0.0541 -0.1151 -0.1186 0.0030 
Δu-Alb               1.0000 0.0372 -0.1346 -0.0504 -0.1058 
ΔTotal-C      * *         1.0000 0.8408* 0.2569* 0.0197 
ΔLDL-C         * * *     * 1.0000 0.1360 -0.0551 
ΔHDL-C *  *   *     *     *  1.0000 -0.4355* 
ΔTG *  *               * 1.0000 
Correlations among the changes in various parameters after 12 months of dapagliflozin administration (or final observation) were analyzed using Spearman’s rank 
correlation coefficient. Missing values were supplemented using the last observation carried forward method. *p < 0.05  
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Table 6 Patient characteristics that affected the changes in HbA1c and BMI 






Standard error t-value p-value 
HbA1c -0.4619 0.0687 -6.7212 < 0.001** 
HDL-C 0.0120 0.0061 1.9546 0.0537 






Standard error t-value p-value 
Sex# 0.4950 0.2160 2.2911 0.0242* 
Disease 
duration 
-0.0395 0.0177 -2.2344 0.0279* 
Patient characteristics that affected the changes in HbA1c and BMI after 12 months of 
dapagliflozin administration (or last observation) were identified through multiple regression 
analysis (stepwise method) with baseline age, sex, disease duration, HbA1c, BMI, systolic blood 
pressure, ALT, eGFR, and HDL-C as the explanatory variables. Missing values were 
supplemented using the last observation carried forward method. Explanatory variables not 
shown in the table were eliminated from the regression formula using the stepwise method. 
*p < 0.05, **p < 0.01 (n = 95), #To analyze sex, male was treated as 1 and female as 0. 
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Supplement 1 Effect of the type of anti-diabetic drug prescribed before dapagliflozin on the 
changes in HbA1c and body weight after 12 months of dapagliflozin   
 
  Change in body HbA1c Change in body weight 
Glucose-lowering drugs  mean ± SD p mean ± SD p 
Biguanide 
+ -0.64 ± 0.83 
0.7313 
-0.31 ± 2.85 
0.2955 
- -0.72 ± 1.23 -2.52 ± 2.72  
DPP-4 inhibitors 
+ -0.62 ± 0.83 
0.5817 
-3.00 ± 2.63 
0.7853 
- -0.73 ± 1.14 -2.84 ± 3.07 
Sulfonylurea 
+ -0.56 ± 0.93 
0.3814 
-2.96 ± 2.91 
0.9527 
- -0.73 ± 1.00 -2.92 ± 2.78  
Thiazolidinediones 
+ -0.27 ± 0.74 
0.0935 
-3.57 ± 3.48 
0.5235 
- -0.71 ± 0.99 -2.86 ± 2.73 
α-glucosidase inhibitors 
+ -0.68 ± 0.78 
0.9438 
-3.44 ± 2.58 
0.5838 
- -0.67 ± 0.99 -2.89 ± 2.84 
Meglitinides 
+ -1.6 ± 3.0 
0.7298 
-3.75 ± 3.89 
0.8130 
- -0.65 ± 0.94 -2.92 ± 2.81 
GLP-1 receptor agonists 
+ -0.73 ± 1,67 
0.9244 
-4.30 ± 2.55 
0.2812 
- -0.66 ± 0.94 -2.86 ± 2.82 
Insulin 
+ -0.97 ± 1.37 
0.1558 
-2.83 ± 2.06 
0.8017 
- -0.57 ± 0.80 -2.97 ± 3.01 
 
Correlations between the type of anti-diabetic drugs and the changes in HbA1c and body weight 




Legends to figures 
Figure 1 Changes in HbA1c over time 
The data are expressed as the means ± standard deviation. Missing values were supplemented 
using the last observation carried forward method. 
*p < 0.01 (vs. start of administration, ANOVA followed by multiplicity test with Holm method) 
 
Figure 2 Changes in body weight over time 
The data are expressed as the means ± standard deviation. Missing values were supplemented 
using the last observation carried forward method. 
*p < 0.01 (vs. start of administration, ANOVA followed by multiplicity test with Holm method) 
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